Center for Vaccine Development Seeks Volunteers for Tuberculosis Vaccine Research
The purpose of this study is to develop a BCG challenge model that can be used to evaluate the protection against infection made by new investigational TB vaccines and strategies, as well as identify factors related to protection against mycobacteria.
The Center for Vaccine Development at Saint Louis University needs volunteers ages 18 to 45 for a study involving an investigational tuberculosis (TB) vaccine.
Those who have received the BCG vaccine will not be eligible.
Background and Purpose:
Tuberculosis has been declared a global health emergency by the World Health Organization (WHO). Mycobacterium tuberculosis (Mtb) is the primary cause of TB and infects nearly one-third of the world’s population. TB is responsible for eight million new cases as well as two million deaths each year, making it one of the world’s most deadly infectious agents and one that causes more adult deaths than any other pathogen.
There is a vaccine that is used to protect against TB infection and complications. It is called Bacillus Calmette-Guerin (BCG). Current standard BCG vaccines have been used for about 60 years and are relatively safe and inexpensive to make and help protect people against the worst forms of TB disease. But these do not prevent infection, chronic latent (inactive) TB infection or the risks of TB disease progression. Worldwide, there is a great need for a more effective vaccine against TB.
The purpose of this study is to develop a BCG challenge model that can be used to evaluate the protection against infection made by new investigational TB vaccines and strategies, as well as identify factors related to protection against mycobacteria.
Payment and Time Commitment:
Participants will be compensated $75 after each completed visit and $10 for the phone call for time and travel.
The study lasts approximately seven to eight months, and there will be 20 to 22 visits.
To learn more about this study or other studies, contact the Center for Vaccine Development at 314-977-6333 or 1-866-410-6333 (toll free), or by email at vaccine@slu.edu. Refer to study number #298.
Saint Louis University IRB #22975; Approved 05-12-14; Board #3